Menu
Search

VC in Residence

Pureos Bioventures

Age of VC

6 years

Team size

24 people

Locations

Pfäffikon, SZ

LinkedIn
Website
Portfolio

Fund volume

aprrox. USD 370M in AuM

Focus stage / Vertical geographic 

Preclinical to clinical PoC, strong focus on Europe, in particular Switzerland 

Top 3 investments 

Zurich-based biotech building a next-gen antibody-drug conjugate (ADC) platform using site-specific linker technology. Raised major Series A/B rounds to advance a pipeline of targeted cancer therapies.

Biotech company focused on bringing novel therapeutic options to patients with severe neurological disorders. The lead project is targeting aberrantly expressed kainate receptors in the hippocampus of patients with refractory TLE using a gene therapy approach. Acquired by uniQure.

ImCheck Therapeutics is developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel superfamily of immunomodulators. By unlocking the power of γ9δ2 T cells, ImCheck’s innovative approach has the potential to transform treatments across oncology, autoimmune, and infectious diseases.

Founding Partner

Dominik Escher

Dominik is a founding partner of Pureos and a co-founder and Executive Chairman of CDR-Life. Previously, he was a founder and CEO of ESBATech, which was acquired in 2009 by Alcon (Novartis) for USD 589 million. As a biotech entrepreneur, he raised USD 90 million for ESBATech to develop novel antibody fragments from discovery to maturity, delivering multiple clinically successful products (e.g., Brolucizumab). Since 2002 he was a Board Member of the Swiss Biotech Association, the biotech industry organization of Switzerland which he led as President from 2013 to 2022. Dominik obtained his PhD in Molecular Biology from the University of Zurich.